Glass Lewis backs Pacira BioSciences director nominees
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall St futures gain on Mideast deal hopes; healthcare in focus
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- Morgan Stanley Downgrades Circle Internet Group (CRCL) to Underweight
- Myanmar's detained former leader Aung San Suu Kyi meets Red Cross official
- Supernus and Indivior agree to all-stock merger of equals
- Curium to acquire Lantheus in deal valued at up to $8 billion
- T1 Energy signs 641MW solar module deal with Clearway Energy Group
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees
May 28, 2026 4:20 PM EDTBRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the Company or Pacira), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that leading independent proxy advisory firm Glass Lewis & Co., LLC (Glass Lewis) has recommended that Pacira stockholders vote FOR each of Paciras three director nominees Christopher Christie, Samit Hirawat, MD and Thomas Wiggans and AGAINST all three of DOMA Perpetual Capital Management LLCs (DOMA Perpetual or DOMA)1 nominees on the BLUE proxy card ahead of the Companys 2026... More
